# Regulation of B cell development and lymphocyte function by transcriptional coactivator OCA-B

**Authors:** Xiangdong Lu, Robert G. Roeder

PMC · DOI: 10.3389/fimmu.2026.1764360 · 2026-03-19

## TL;DR

OCA-B is a key coactivator in B cell development and immune function, with implications in disease and potential as a therapeutic target.

## Contribution

This paper highlights OCA-B's novel roles in regulating B cell and T cell gene expression and its relevance to disease.

## Key findings

- OCA-B is essential for Germinal Center formation and secondary immunoglobulin gene transcription.
- OCA-B regulates gene expression in both B cells and CD4+ memory T cells.
- OCA-B has a role in B-cell malignancy and autoimmune diseases, suggesting therapeutic potential.

## Abstract

OCA-B (OCT Coactivator from B cells) is highly expressed in B cells and is the first-identified tissue-specific transcriptional coactivator. Mechanistically, OCA-B is recruited to target genes through primary interactions with DNA-binding transcription factors OCT1/OCT2, as well as secondary interactions with MEF2B, and its effector functions in activating transcription involve interactions with the Mediator coactivator complex. Physiologically, OCA-B plays an essential role in antigen-stimulated Germinal Center (GC) formation and transcription of secondary immunoglobulin (Ig) genes. OCA-B also regulates bone marrow and peripheral B cell development. While GC B cell-specific inactivation of Oca-B is sufficient to cause GC defects, OCA-B function in follicular T helper (Tfh) cells also plays an important role in GC reactions. In GC B cells, OCA-B–dependent genes include known GC regulatory genes such as Bcl6, Mef2b and Irf4. In CD4+ memory T cells, OCA-B is required to maintain a subset of genes, including Il2, in a transcriptionally poised state, enabling their rapid and robust up-regulation upon repeated stimulation. Moreover, recent studies have indicated an essential role for OCA-B in B-cell malignancy and multiple autoimmune diseases, highlighting OCA-B as a potential therapeutic target for these diseases.

## Linked entities

- **Genes:** POU2AF1 (POU class 2 homeobox associating factor 1) [NCBI Gene 5450], BCL6 (BCL6 transcription repressor) [NCBI Gene 604], MEF2B (myocyte enhancer factor 2B) [NCBI Gene 100271849], IRF4 (interferon regulatory factor 4) [NCBI Gene 3662], IL2 (interleukin 2) [NCBI Gene 3558]
- **Proteins:** POU2AF1 (POU class 2 homeobox associating factor 1), POU2F1 (POU class 2 homeobox 1), POU2F2 (POU class 2 homeobox 2), MEF2B (myocyte enhancer factor 2B)

## Full-text entities

- **Genes:** Pou2f1 (POU domain, class 2, transcription factor 1) [NCBI Gene 18986] {aka 2810482H01Rik, NF-A1, Oct-1, Oct1, Otf-1, Otf1}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Pou2f2 (POU domain, class 2, transcription factor 2) [NCBI Gene 18987] {aka Oct-2, Oct2a, Oct2b, Oct2c, Oct2d, Otf-2}, Pou2af1 (POU domain, class 2, associating factor 1) [NCBI Gene 18985] {aka BOB.1, Bob-1, Bob1, OBF-1, OBF.1, OCA-B}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Mef2b (myocyte enhancer factor 2B) [NCBI Gene 17259], Irf4 (interferon regulatory factor 4) [NCBI Gene 16364] {aka IRF-4, LSIRF, NF-EM5, Spip}, Bcl6 (B cell leukemia/lymphoma 6) [NCBI Gene 12053] {aka Bcl5}
- **Diseases:** autoimmune diseases (MESH:D001327), B-cell malignancy (MESH:D016393)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13043367/full.md

---
Source: https://tomesphere.com/paper/PMC13043367